178 related articles for article (PubMed ID: 37415003)
1. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.
Takahashi T; Jaber MM; Brown SJ; Al-Kofahi M
Clin Pharmacokinet; 2023 Jul; 62(7):955-968. PubMed ID: 37415003
[TBL] [Abstract][Full Text] [Related]
2. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
[TBL] [Abstract][Full Text] [Related]
6. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
[TBL] [Abstract][Full Text] [Related]
7. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
Takahashi T; Illamola SM; Jennissen CA; Long SE; Lund TC; Orchard PJ; Gupta AO; Long-Boyle JR
Transplant Cell Ther; 2022 Feb; 28(2):104.e1-104.e7. PubMed ID: 34883294
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.
Wu X; Xie H; Lin W; Yang T; Li N; Lin S; Yuan X; Ren J; Li X; Huang X
Clin Exp Pharmacol Physiol; 2017 May; 44(5):529-538. PubMed ID: 28135768
[TBL] [Abstract][Full Text] [Related]
9. Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children.
Marsit H; Philippe M; Neely M; Rushing T; Bertrand Y; Ducher M; Leclerc V; Guitton J; Bleyzac N; Goutelle S
Clin Pharmacokinet; 2020 Aug; 59(8):1049-1061. PubMed ID: 32157629
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
11. Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
Lawson R; Staatz CE; Fraser CJ; Hennig S
Clin Pharmacokinet; 2021 Jan; 60(1):17-51. PubMed ID: 33128207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
13. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
McCune JS; Bemer MJ; Barrett JS; Scott Baker K; Gamis AS; Holford NH
Clin Cancer Res; 2014 Feb; 20(3):754-63. PubMed ID: 24218510
[TBL] [Abstract][Full Text] [Related]
14. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
[TBL] [Abstract][Full Text] [Related]
15. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
Booth BP; Rahman A; Dagher R; Griebel D; Lennon S; Fuller D; Sahajwalla C; Mehta M; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):101-11. PubMed ID: 17192508
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
Lawson R; Staatz CE; Fraser CJ; Ramachandran S; Teague L; Mitchell R; O'Brien T; Hennig S
CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1002-1017. PubMed ID: 35611997
[TBL] [Abstract][Full Text] [Related]
18. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
Takama H; Tanaka H; Nakashima D; Ueda R; Takaue Y
Bone Marrow Transplant; 2006 Feb; 37(4):345-51. PubMed ID: 16400337
[TBL] [Abstract][Full Text] [Related]
20. Can Published Population Pharmacokinetic Models of Busulfan Be Used for Individualized Dosing in Chinese Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? An External Evaluation.
Huang H; Liu M; Ren J; Hu J; Lin S; Li D; Huang W; Chen S; Yang T; Wu X
J Clin Pharmacol; 2022 May; 62(5):609-619. PubMed ID: 34695225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
